Title

15485 Evaluating the safety and efficacy of intense pulsed light with radiofrequency in US patients with hidradenitis suppurativa: A split-body study

Document Type

Conference Proceeding

Publication Date

12-2020

Publication Title

J Am Acad Dermatol

Abstract

Laser and light-based treatments for hidradenitis suppurativa (HS) have gained popularity and are thought to work by: targeting melanin in the hair follicle leading to laser-induced hair removal, debulking, sebaceous gland reduction, or bacterial load reduction. Laight therapy (Lenicura, Germany) is a European Union approved, treatment for HS and acne, utilizing intense pulsed light (IPL) with radiofrequency (RF). IPL is believed to cause photothermolysis, where the absorption of light by chromophores in the skin creates heat to target the blood vessels that supply sebaceous glands to reduce sebum production and cause thermal damage to hair follicles. Similarly, it is hypothesized that RF causes thermal damage, inhibits sebaceous gland activity, and induces collagen production and collagen fiber remodeling in the dermis. The objective of this study was to determine the safety and efficacy of IPL+RF in US patients with HS. Two subjects (Hurley Stage II and III) underwent IPL+RF treatments every 2 weeks for a total of 10 treatments to a randomized half of the body. Clinical assessments and patient reported outcomes were obtained at each visit. One patient had a 3-point improvement in the Dermatology Life Quality Index (DLQI) and the other had a 1-point worsening in DLQI, but no improvement in clinical outcomes (Hurley Staging-Physician Global Assessment [HSPGA], Hidradenitis Suppurativa Clinical Response [HiSCR], International Hidradenitis Suppurativa Severity Score System [IHS4]) were observed for either patient. No adverse events were reported. While this study is ongoing, larger studies are needed to further evaluate the safety and efficacy of this treatment.

Volume

83

Issue

6

First Page

AB154

This document is currently not available here.

Share

COinS